Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 4, 1997, Pages 759-762

  Hong, Jun Yan ^a   Yang, Chung S ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Biomarker; Cancer risk; Cytochrome P450; Environmental toxicity; Genetic polymorphisms; Metabolism; Susceptibility

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450; TOXIC SUBSTANCE;

CANCER RISK; CONFERENCE PAPER; ENVIRONMENTAL HEALTH; GENETIC POLYMORPHISM; HEALTH HAZARD; METABOLIC ACTIVATION; PRIORITY JOURNAL;

EID: 0030819023     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s4759     Document Type: Conference Paper

References (32)

1. Guengerich FP. Human cytochrome P450 enzymes. Life Sci 50:1471-1478 (1992).
2. Nelson DR, Kanmataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1-51 (1993).
3. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 102:55-60 (1994).
4. Pelkonen O, Raunio H. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ Health Perspect 105(Suppl 4):767-774 (1997).
5. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21 (1992).
6. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 57:129-160 (1993).
7. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and acetyltransferase phenotype in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127 (1992).
8. Vanden Heuvel JP, Clark GC, Thompson CL, McCoy Z, Miller CR, Lucier GW, Bell DA. CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 14:2003-2006 (1993).
9. Yang CS, Brady JF, Hong J-Y. Dietary effects on cytochromes P-450, xenobiotic metabolism, and toxicity. FASEB J 6:737-744 (1992).
10. Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver by ethanol and drug intake. Eur J Clin Invest 19:549-555 (1989).
11. Vistisen K, Loft S, Poulsen HS. Cytochrome P4501A2 activity in man measured by caffeine metabolism: effect of smoking, broccoli, and exercise. In: Biological Reactive Intermediates IV: Molecular and Cellular Effects and Their Impact on Human Health. Vol 283 (Witmer C, Snyder R, Jollow D, Kalf G, Kocsis J, Sipes I, eds). New York:Plenum Press, 1991;407-411.
12. Kalow W, Tang BK. Caffeine as a metabolite probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44-48 (1991).
13. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:363-372 (1988).
14. Gonzales FJ, Skoda R, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446 (1988).
15. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Mutiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214 (1990).
16. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphisms. Proc Nad Acad Sci USA 86:2766-2770 (1989).
17. Cariello NF, Skopek TR. Mutational analysis using denaturing gradient gel electrophoresis and PCR. Mutat Res 288:103-112 (1993).
18. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. The genetic and metabolic criteria for the assignment of debrisoquine hydroxylation (cytochrome P450IID6) phenotypes. Pharmacogenetics 1:33-41 (1991).
19. Hayashi S, Watanbe J, Nakachi K, Kawagiri K. Genetic linkage of lung cancer-associated MsfI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 110:407-411 (1991).
20. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29:1322-1329 (1990).
21. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Letter 263:131-133 (1990).
22. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in Afrcian-American women. Cancer Res 55:3757-3758 (1995).
23. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen A-L. Human CYP1A1 (cytochrome P450 P1450) gene: lack of association between the MspI restriction fragment length polymorphism and the incidence of lung cancer in a Norwegian population. Pharmacogenetics 1:20-25 (1991).
24. Wolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mill K, McNee W, Carmichael J et al. Relationship between the debrisoquine hydroxylase polymor-phism and cancer susceptibility. Carcinogenesis 13:1035-1038 (1992).
25. Hidesheim A, Chen C-J, Caporaso NE, Cheng Y-J, Hooever RN, Hsu M-M, Levine PH, Chen I-H, Chen J-Y, Yang CS et al. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarkers Prev 4:607-610 (1995).
26. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14:85-88 (1993).
27. Kato S, Shields PG, Caporaso NE, Sugimura H, Trivers GE, Tucker MA, Trump B, Weston A, Harris CC. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev 3:515-518 (1994).
28. Yu M-W, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw Y-F, Chen C-J. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 109:1266-1273 (1995).
29. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene ana susceptibility to lung cancer. Jpn J Cancer Res 82:254-256 (1991).
30. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, Weston A, Harris CC. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52:6712-6715 (1992).
31. Hayashi S-I, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 110:559-565 (1991).
32. Hecht SS, Hoffmann D. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surveys 8:273-294 (1989).